G1 Therapeutics is a commercial-stage biopharmaceutical company focused on developing small-molecule therapies to target unmet needs in cancer treatment. They are committed to improving the lives of those affected by cancer and have a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors. They are also advancing a potential best-in-class oral selective estrogen receptor degrader for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.